PCN262 PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL

Autor:	C. Dehner, Donald L. Patrick, Karen Chung, J. Garcia, Y. Kim, L. Matza
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Health Policy Internal medicine Relapsed refractory Public Health Environmental and Occupational Health medicine In patient medicine.disease business Diffuse large B-cell lymphoma Preference
Zdroj:	Value in Health. 22:S106
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9db6324652886e051aa1d252668a0176 https://doi.org/10.1016/j.jval.2019.04.383 Zobrazit plný text záznamu Full Text from ScienceDirect